Women who begin potent anti-HIV therapy during pregnancy achieve undetectable viral loads more quickly with nevirapine-based compared to nelfinavir-based regimens, according to findings from the European Collaborative Study. Results published in the June 15th issue of Clinical Infectious Diseases also showed that women of western African origin achieved viral suppression more quickly than non-African women.